Ensuring timely antibody supply during the COVID-19 pandemic - contact us for solutions

Goat Anti-Human IgG Fc-FITC

Cat. No.:
2048-02
Goat Anti-Human IgG Fc-FITC antibody for use in western blot and for other fluorescent assays.
$65.00
Size Price (USD) Quantity
0.5 mg $65.00
More Information
Isotype Goat IgG
Isotype Control Goat IgG-FITC
Specificity Reacts with the Fc region of human IgG
Source Pooled antisera from goats hyperimmunized with human IgG
Cross Adsorption Human IgG Fab, IgM, and IgA; may react with IgG from other species
Purification Method Affinity chromatography on human IgG Fc covalently linked to agarose
Conjugate FITC (Fluorescein)
Buffer Formulation Phosphate buffered saline containing < 0.1% sodium azide
Clonality Polyclonal
Concentration 0.5 mg/mL
Volume 1.0 mL
Recommended Storage 2-8°C; Avoid exposure to light
Applications Quality tested applications for relevant formats include -
ELISA 1
FLISA

Other referenced applications for relevant formats include -
Western Blot 2,3
Surface Plasmon Resonance 4
RRID Number AB_2795686

Certificate of Analysis Lookup

Enter the Catalog Number and Lot Number for the Certificate of Analysis you wish to view


Need help with this product?
or call 800.722.2255
  1. 1. Wang Q, Chen K, Liu F, Zhao F, Gupta S, Zhang N, et al. Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist. PLoS One. 2010;5(9):e12734. (ELISA)
  2. 2. Shen X, Hu G, Jiang S, He F, Xing W, Li L, et al. Engineering and characterization of a baculovirus-expressed mouse/human chimeric antibody against transferrin receptor. Protein Eng Des Sel. 2009;22:723-31. (WB)
  3. 3. Djoumerska-Alexieva IK, Dimitrov JD, Voynova EN, Lacroix-Desmazes S, Kaveri SV, Vassilev TL. Exposure of IgG to an acidic environment results in molecular modifications and in enhanced protective activity in sepsis. FEBS J. 2010;277:3039-50. (WB)
  4. 4. Kaymakcalan Z, Sakorafas P, Bose S, Scesney S, Xiong L, Hanzatian DK, et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol. 2009;131:308-16. (Surface Plasmon Resonance)